The present authors carried out an open up-label pilot analyze that administered psilocybin to fifteen therapy-resistant tobacco/nicotine-dependent smokers, from the context of cognitive behavioral therapy for using tobacco cessation [fifty eight]. Participants had been administered ~0.29 mg/kg oral